Diaper dermatitis management: A global and innovative strategy for a new generation of skin care

Diaper rash affects up to 35% of infants with a peak around 10-12 months. Our research program on infant skin, focused on the epidermis, provided some evidences: barrier function is developing, inflammation signals are present and cellular resource needs to be preserved. The main causes of diaper rash are: altered barrier function and inflammation. We developed a new product containing zinc oxide associated with 3 patented natural active ingredients with anti-irritant, anti-enzymatic and repairing activities.
Two clinical trials (preventive/curative) were conducted on 60 and 62 infants during 30 days. In the preventive study, the number of diaper rashes was reduced by 88%. During the curative trial, erythema intensity and surface were decreased by 82% after D1. A total response was observed in 54% of children after D3.
The irritant action of urine on a 1 year-aged reconstructed epidermis was modeled and evaluated in vitro. The product was able to restore barrier markers, to preserve stem cells markers and to clearly modulate inflammatory mediators by 36% (IL1a, IL8), 82% (PGE2) and 70% (TRPV1, TACR1). The product enabled the tissue recovery even after urine treatment with a viability of 97%.
The new formulation provides a global strategy for the management of diaper rash. By its specific composition, it exhibits a good barrier protection and repair and potent anti-inflammatory properties in vitro that are correlated with clinical results. Indeed, the product prevents apparition of diaper rash, soothes pain and redness from the first application and offers a lasting repair.

Ms Gaelle Bellemere